Last reviewed 2026-05-25 · How we verify

Glucaron (ACEGLATONE)

Phase 2 active Small molecule ✓ Verified May 2026

Glucaron (generic name: ACEGLATONE) is a drug. It is currently in Phase 2 development.

Glucaron works by binding to and modulating specific biological targets, although the exact mechanism is not yet fully understood.

Glucaron is a small molecule with synonyms including ACEGLATONA, ACEGLATONE, and GLUCARON.

Likelihood of approval

15.3% vs 15.3% industry baseline

If approved by FDA: likely 2031–2034

Steps remaining: Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 2 → approval rate +15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2031–2034	—
EMA	EU	2032–2035	+0.7 yr
MHRA	GB	2032–2035	+0.7 yr
Health Canada	CA	2032–2036	+0.9 yr
TGA	AU	2032–2036	+1.2 yr
PMDA	JP	2032–2036	+1.5 yr
NMPA	CN	2033–2037	+2.3 yr
MFDS	KR	2032–2036	+1.4 yr
CDSCO	IN	2032–2037	+1.8 yr
ANVISA	BR	2033–2037	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	ACEGLATONE
Modality	Small molecule
Therapeutic area	Other
Phase	Phase 2

Mechanism of action

Imagine your body's cells are like a orchestra, and each cell has its own specific role to play. Glucaron is like a conductor that helps the cells work together in harmony, but we don't yet know exactly how it does this. By understanding how Glucaron interacts with the cells, we can learn more about how it might help treat certain diseases.

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Glucaron CI brief — competitive landscape report
Glucaron updates RSS · CI watch RSS

Frequently asked questions about Glucaron

What is Glucaron?

Glucaron (ACEGLATONE) is a Small molecule drug.

How does Glucaron work?

Glucaron works by binding to and modulating specific biological targets, although the exact mechanism is not yet fully understood.

What is the generic name of Glucaron?

ACEGLATONE is the generic (nonproprietary) name of Glucaron.

What development phase is Glucaron in?

Glucaron is in Phase 2.

Therapeutic area: All drugs in Other

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing